Burundi vs Eswatini: Access to anti-retroviral drugs, female
Burundi
98.0%
in 2024
Eswatini
98.0%
in 2024
Burundi rank
1st
Eswatini rank
1st
Access to anti-retroviral drugs, female over time
- Burundi
- Eswatini
How they compare
Burundi currently reports 98.0% against 98.0% in Eswatini, a difference of 0.0%.
The two have swapped places 4 times across 25 shared years of data; in 2000 it was Eswatini ahead.
Burundi ranks 1st and Eswatini ranks 1st of 141 countries.
Eswatini has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Burundi | Eswatini | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 7.0% | 7.7% | 0.7% | Eswatini |
| 2010s | 56.2% | 64.4% | 8.2% | Eswatini |
| 2020s | 95.6% | 97.4% | 1.8% | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Burundi or Eswatini?
- Burundi, at 98.0% against 98.0% in Eswatini as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Burundi and Eswatini?
- 0.0%, with Burundi ahead.
- How many years of comparable data are there for Burundi and Eswatini?
- 25 years are reported by both, from 2000 to 2024.
- How do Burundi and Eswatini rank globally for access to anti-retroviral drugs, female?
- Burundi ranks 1st and Eswatini ranks 1st of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.